Microbix Biosystems (TSX:MBX) FCF Margin % : 9.76% (As of Dec. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Microbix Biosystems's Free Cash Flow for the three months ended in Dec. 2024 was C$0.59 Mil. Microbix Biosystems's Revenue for the three months ended in Dec. 2024 was C$6.04 Mil. Therefore, Microbix Biosystems's FCF Margin % for the quarter that ended in Dec. 2024 was 9.76%.

As of today, Microbix Biosystems's current FCF Yield % is 3.59%.

The historical rank and industry rank for Microbix Biosystems's FCF Margin % or its related term are showing as below:

TSX:MBX' s FCF Margin % Range Over the Past 10 Years
Min: -47.86 Med: -5.58 Max: 9.61
Current: 7.5

During the past 13 years, the highest FCF Margin % of Microbix Biosystems was 9.61%. The lowest was -47.86%. And the median was -5.58%.

TSX:MBX's FCF Margin % is ranked better than
83.23% of 1002 companies
in the Biotechnology industry
Industry Median: -121.695 vs TSX:MBX: 7.50

Microbix Biosystems FCF Margin % Historical Data

The historical data trend for Microbix Biosystems's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems FCF Margin % Chart

Microbix Biosystems Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

FCF Margin %

Get a 7-Day Free Trial

-7.65

4.32

7.54

-12.78

9.61

Microbix Biosystems Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															15.49	3.57	7.91	8.53	9.76

Competitive Comparison of Microbix Biosystems's FCF Margin %

For the Biotechnology subindustry, Microbix Biosystems's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbix Biosystems's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Microbix Biosystems FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Microbix Biosystems's FCF Margin for the fiscal year that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2024 )	/	Revenue (A: Sep. 2024 )
	=	2.441	/	25.394
	=	9.61 %

Microbix Biosystems's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0.59	/	6.044
	=	9.76 %

Microbix Biosystems FCF Margin % Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbix Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MBXBF:USA

Address

265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website

https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and; Development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.

Executives

James Stuart Currie	Senior Officer
Mark Adrian Luscher	Senior Officer
Bo Hollas	Director
Jennifer Anne Stewart	Director
Cameron Lionel Groome	Director, Senior Officer
Kenneth Hughes	Senior Officer
Martin Marino	Director
Peter Martin Blecher	Director
Philip Jonathan Casselli	Senior Officer
Steven Trevor Hagerman	Senior Officer
Damian Klimaszewski	Senior Officer
Anthony J. Giovinazzo	Director